Researchers have announced the FDA approval of VEPPANU (vepdegestrant), marking it as the first-ever PROTAC therapy approved in the U.S. This new treatment option targets advanced or metastatic breast cancer that is estrogen receptor-positive, HER2-negative, and has an ESR1 mutation. This approval comes as a significant advancement, especially for patients who have limited treatment options after their initial therapies fail.

For those living with this specific type of breast cancer, VEPPANU offers hope by potentially improving progression-free survival. In a clinical trial involving 270 patients with ESR1 mutations, VEPPANU demonstrated a 43% reduction in the risk of disease progression or death compared to the standard treatment, fulvestrant. The median progression-free survival was 5 months for VEPPANU compared to just 2.1 months for fulvestrant, suggesting that this new oral medication could provide a critical lifeline for individuals facing aggressive cancer progression.

The research supporting VEPPANU is based on the Phase 3 VERITAC-2 clinical trial, which included 624 participants and showed strong evidence of the drug’s effectiveness. While the results are promising, it’s important to note that the overall survival data is still developing, and more research is needed to fully understand the long-term benefits and risks associated with this treatment.

If you or someone you know is dealing with advanced breast cancer, discussing VEPPANU with a healthcare provider may be worthwhile, especially if previous treatments have not been effective. This new option could be a significant addition to the treatment landscape for those with ESR1 mutations.

Source: globenewswire.com